Moderna Sales Get Lift From Early Nod

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back.
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The Centers for Disease Control and Prevention (CDC) recommends the Moderna and Pfizer-BioNTech COVID-19 vaccines for ...